Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance
Organoids · 30.03.2026 · 5 (2) · 10
DOI: 10.3390/organoids5020010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organoids, online erschienen am 30.03.2026. Verfasst von Mingyang Kong und 22 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense, Cancer Research UK Grand Challenge, Montreal General Hospital Foundation.
Abstract (Originalsprache)
A major limitation in studying gastroesophageal adenocarcinoma (GEA) has been the lack of reliable models that represent the disease’s complexity. We present lessons learned from a comprehensive large-scale biobanking effort combining traditional sample collection with several in vitro models, including 3-dimensional patient-derived organoids (PDOs), 2-dimensional cancer-associated fibroblasts (CAFs), tumor-infiltrating lymphocytes (TILs), and/or in vivo xenografts. This initiative started in 2018, integrating multiple advanced ex vivo models such as PDOs, patient-derived xenografts (PDXs), and organoids (PDXOs). This unique resource now includes tumor avatars from over 380 consented patients, making it the world’s largest living GEA biobank. We achieved a >90% success rate in creating per-patient models, including 227 tumor-derived and 203 neighboring normal PDOs. These organoids accurately mirror key features of the original tumors, such as their histology (e.g., microsatellite instability), mutations, and drug response across treatment points. Notably, PDOs can predict individual patient responses to chemotherapy within five weeks, underscoring their clinical relevance. Furthermore, high-throughput drug screening on PDO subsets with known genetic landscapes generates personalized chemosensitivity profiles for 22 drugs. Through a process of continued refinement of culture techniques and tumor sampling approach, our large-scale comprehensive collection of GEA avatars represents a unique and valuable preclinical experimental resource for precision oncology.
Förderung
- Department of Defense
- Cancer Research UK Grand Challenge
- Montreal General Hospital Foundation
- Canadian Cancer Society
- Canadian Institutes of Health Research
Zitieren
APA
Kong, M., Pal, S., Wang, S., Bérubé, J., Ma, R., Yan, Y., Zeng, W., Bourdeau, F., Giannias, B., Zhao, H., Osman, N., Nevo, Y., Tai, K., Kuasne, H., Tankel, J., Evaristo, G., Fiset, P. O., Su, X., Bailey, S., …, & Ferri, L. (2026). Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance. Organoids, 5(2), 10. https://doi.org/10.3390/organoids5020010
Vancouver
Kong M, Pal S, Wang S, Bérubé J, Ma R, Yan Y, et al. Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance. Organoids. 2026;5(2):10. doi:10.3390/organoids5020010
BibTeX
@article{Kong2026,
author = {Kong, Mingyang and Pal, Sanjima and Wang, Shuyuan and Bérubé, Julie and Ma, Ruoyu and Yan, Yifei and Zeng, Wotan and Bourdeau, France and Giannias, Betty and Zhao, Hong and Osman, Nathan and Nevo, Yehonatan and Tai, Kulsum and Kuasne, Hellen and Tankel, James and Evaristo, Gertruda and Fiset, Pierre O. and Su, Xin and Bailey, Swneke and Park, Morag and Bertos, Nicholas and Sangwan, Veena and Ferri, Lorenzo},
title = {Optimized Large-Scale Longitudinal Biorepository of Gastroesophageal Adenocarcinoma Patient-Derived Organoids: High-Fidelity Models for Personalized Treatment to Overcome Resistance},
journal = {Organoids},
year = {2026},
volume = {5},
number = {2},
pages = {10},
doi = {10.3390/organoids5020010}
}
EUVIMED